Swiss healthcare company Galderma has initiated a phase II clinical trial on a liquid formulation of botulinum toxin to be used in aesthetic dermatology and cosmetic surgery.
According to a Galderma news release, the multicenter, dose-ranging study is designed to evaluate the safety and effectiveness of Galderma’s internally developed liquid form of botulinum toxin for the treatment of glabellar lines. Galderma officials say a liquid formulation has the potential to offer physicians a ready-to-use product that may result in a better patient experience and improved outcomes.
The statement quotes Galderma President and C.E.O. Humberto C. Antunes as saying, “The development of a liquid neurotoxin represents a significant advancement over existing commercial products and would allow us to further strengthen our position in the aesthetic category by better meeting physician and patient needs.”
This summer Galderma acquired the U.S. and Canadian rights to a portfolio of injectables. The company also announced the strengthening of its collaboration with Ipsen in the development and commercialization of new neurotoxins.